PPARG and Cerebral ischemia: Han and colleagues [197] showed that treatment with the PPAR-γ agonist rosiglitazone, improves long-term white matter integrity after cerebral ischemia, at least, in part, by promoting oligodendrogenesis and facilitating microglial polarization toward the beneficial M2 phenotype.